ALEC - Alector: Brain Science Play With High Expenses And Few Catalysts
2024-07-12 16:48:36 ET
Summary
- Alector's lead pipeline assets are for challenging brain disorders.
- Ample liquidity assures that Alector can develop its lead assets over the near term.
- Its lead pipeline candidates generate milestone revenues.
- With a high expense profile and faltering revenues, Alector is a high-risk investment.
This is my second Alector ( ALEC ) article, following 10/2023's "Alector: Milestone Uncertainty Plus Lack Of Product Revenue" ("Uncertainty"). In uncertainty, I rated Alector a hold. It was trading at $6.07 at the time. It has since dropped ~11%....
Alector: Brain Science Play With High Expenses And Few Catalysts